Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation

Blood

Volumn 120, Issue 2, 2012, Pages 386-394

  Roth, Michael ^a,b   Will, Britta ^b   Simkin, Guillermo ^b   Narayanagari, Swathi ^b   Barreyro, Laura ^b   Bartholdy, Boris ^b   Tamari, Roni ^b   Mitsiades, Constantine S ^c,d   Verma, Amit ^b   Steidl, Ulrich ^b  

^a CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; DEFEROXAMINE; ELTROMBOPAG; IRON;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL DIVISION; CELL PROLIFERATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84864053179     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-399667     Document Type: Article

References (39)

1. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249-1259.
2. Miyawaki S, Ohtake S, Fujisawa S, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 2011;117(8):2366.
3. Petersdorf S, Kopecky K, Stuart R, et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to postconsolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114:790.
4. Rowe JM, Tallman MS. How I treat acute myeloid leukemia. Blood. 2010;116(17):3147.
5. Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 2007;109(9):1705-1714. (Pubitemid 46668530)
6. Konstantopoulos K, Lauren L, Hast R, Reizenstein P. Survival, hospitalization and cause of death in 99 patients with the myelodysplastic syndrome. Anticancer Res. 1989;9(4):893.
7. Bussel J, Cheng G, Saleh M, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22): 2237.
8. McHutchison J, Dusheiko G, Shiffman M, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357(22):2227.
9. Mavroudi I, Pyrovolaki K, Pavlaki K, et al. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leuk Res. 2011;35(3):323-328.
10. Will B, Kawahara M, Luciano J, et al. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood. 2009;114(18):3899.
11. Kalota A, Gewirtz AM. A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells. Blood. 2010;115(1):89.
12. Erickson-Miller C, Kirchner J, Aivado M, May R, Payne P, Chadderton A. Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. Leuk Res. 2010; 34(9):1224-1231.
13. Matthys G, Park JW, McGuire S, et al. Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers. J Clin Pharmacol. 2011;51(3):301.
14. Rosenbauer F, Wagner K, Kutok JL, et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU. 1. Nat Genet. 2004;36(6):624-630. (Pubitemid 38715991)
15. Steidl U, Rosenbauer F, Verhaak R, et al. Essential role of Jun family transcription factors in PU. 1 knockdown-induced leukemic stem cells. Nat Genet. 2006;38(11):1269-1277. (Pubitemid 44646289)
16. Erickson-Miller C, Delorme E, Tian S, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009;27(2):424-430.
17. Jenkins J, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007; 109(11):4739.
18. Conde P. Fluorescence reactions of erichrome red b with metals. Part I: detection of Be, Mg, Al, In, Ga, and Zn. Analytica Chimica Acta. 1974; 73(1):191-193.
19. Fisher AEO, Naughton D. Zinc (II) complex of the EDTA bis (tyrosine) chelating agent. J Structural Chem. 2007;48(4):711-714.
20. Callens C, Coulon S, Naudin J, et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med. 2010;207(4): 731.
21. Fu D, Richardson DR. Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood. 2007;110(2):752.
22. Lipiński P, Drapier JC, Oliveira L, Retmaska H, Sochanowicz B, Kruszewski M. Intracellular iron status as a hallmark of mammalian cell susceptibility to oxidative stress: a study of L5178Y mouse lymphoma cell lines differentially sensitive to H2O2. Blood. 2000;95(9):2960.
23. Mladenka P, Šimunek T, Hübl M, Hrdina Rír. The role of reactive oxygen and nitrogen species in cellular iron metabolism. Free Radic Res. 2006; 40(3):263-272. (Pubitemid 43245441)
24. Pahl PMB, Horwitz LD. Cell permeable iron chelators as potential cancer chemotherapeutic agents. Cancer Invest. 2005;23(8):683-691. (Pubitemid 43045671)
25. Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U SA. 2006;103(40):14901.
26. Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. Blood. 2009;113(16):3655-3665.
27. Rao VA, Klein SR, Agama KK, et al. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells. Cancer Res. 2009;69(3):948.
28. Yuan J, Lovejoy DB, Richardson DR. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood. 2004;104(5):1450.
29. Chou FS, Mulloy JC. The Thrombopoietin/MPL pathway in hematopoiesis and leukemogenesis. J Cell Biochem. 2011;112(6):1491-1498.
30. Sitnicka E, Lin N, Priestley G, et al. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood. 1996;87(12):4998.
31. Wetzler M, Baer M, Bernstein S, et al. Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy. J Clin Oncol. 1997;15(6):2262.
32. Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010;28(3):437.
33. Duffy KJ, Price AT, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho [1, 2-d] imidazole thrombopoietin mimics. J Med Chem. 2002;45(17):3576-3578. (Pubitemid 34856097)
34. Duffy KJ, Shaw AN, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 1. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics. J Med Chem. 2002;45(17):3573-3575. (Pubitemid 34856096)
35. Erickson-Miller CL, DeLorme E, Tian SS, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005;33(1):85-93. (Pubitemid 40127647)
36. Williams DD, Peng B, Bailey CK, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, cross-over studies. Clin Ther. 2009;31(4):764-776.
37. Richardson D, Kalinowski D, Lau S, Jansson P, Lovejoy D. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta. 2009; 1790(7):702-717.
38. Richardson DR, Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta. 1997;1331(1):1.
39. Kellum A, Jagiello-Gruszfeld A, Bondarenko I, Patwardhan R, Messam C, Mostafa Kamel Y. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/ paclitaxel for advanced solid tumors. Curr Med Res Opin. 2010;26(10):2339-2346.